Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Allocetra-OTS + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Allocetra-OTS | Allogeneic ex-vivo-treated PBMCs|Allocetra | Allocetra-OTS is a cellular therapy comprising mononuclear cells induced to undergo early apoptosis, which potentially decreases tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). | ||
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05581719 | Phase Ib/II | Allocetra-OTS Allocetra-OTS + Tislelizumab Allocetra-OTS + Nivolumab | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | Terminated | ESP | 1 |